Conference Correspondent

Younger, thinner, nondiabetic men were more likely to gain weight on androgen deprivation therapy (ADT) than older men with comorbidities. Read More ›

The Cancer Genome Atlas (TCGA) project now includes a recently reported comprehensive molecular characterization of muscle-invasive urothelial bladder carcinoma... Read More ›

Building on the theme of appropriate use of procedures and treatments, a new study suggests that cytoreductive nephrectomy (CN) will not alter survival of patients with metastatic renal cell carcinoma (mRCC) with a short life expectancy ( Read More ›

The American Society of Clinical Oncology (ASCO) is again participating in the American Board of Internal Medicine’s (ABIM) Choosing Wisely campaign designed to streamline healthcare delivery. Read More ›

Immunotherapy with ipilimumab improved progression-free survival (PFS) and prostate-specific antigen response compared with placebo, but improvement in overall survival (OS) failed to reach statistical significance in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC)... Read More ›

Men with prostate cancer are often treated with hormone therapy (androgen deprivation therapy [ADT]), but this treatment can have unpleasant and even harmful side effects, including metabolic abnormalities that lead to diabetes mellitus (DM) and cardiovascular disease (CVD). Read More ›

About 7500 participants from more than 90 countries attended the breast cancer symposium. The following are selected brief highlights from these meetings. Read More ›

The keynote address of the Fourth Annual Conference of the Academy of Oncology Nurse & Patient Navigators (AONN+) was delivered by Linda W. Ferris, PhD. Ferris is vice president, Oncology System Service Line, at Centura Health in Colorado and Kansas, as well as chair of the Commission on Cancer (CoC) Accreditation Committee. Read More ›

The 2013 American Society of Clinical Oncology (ASCO) Annual Meeting brought approximately 30,000 cancer specialists to Chicago, Illinois, from May 31 to June 4, 2013. Read More ›

Panelists at the 2013 Annual Conference of the National Comprehensive Cancer Network (NCCN) view the oncology world as rapidly changing, and the impact of this—for better or for worse—will be felt by healthcare providers, payers, and patients alike. Read More ›